Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are on systemic corticosteroids, other immunosuppressive therapy, or anti-coagulation therapies that can't be stopped 24 hours before treatment. Also, you must not have received chemotherapy, radiotherapy, immunotherapy, or other investigational agents within 21 days prior to treatment.
What data supports the idea that Intratumoral IP-001 Injection for Solid Cancers is an effective treatment?
The available research shows that Intratumoral IP-001 Injection can effectively stimulate the body's immune response against cancer. By injecting the treatment directly into the tumor, it helps activate the immune system locally, which can then lead to a broader, long-lasting response throughout the body. This method reduces the risk of severe side effects compared to treatments given through the bloodstream. Studies have shown that this approach can be more effective and safer, especially when combined with other cancer treatments. For example, it has been successful in treating melanoma, a type of skin cancer, and is being tested for other cancers as well.12345
What safety data exists for Intratumoral IP-001 Injection for Solid Cancers?
The provided research does not directly mention IP-001 or its safety data. However, it discusses the safety of intratumoral chemotherapy and immunotherapy approaches, which are relevant to IP-001. Intratumoral delivery of chemotherapy, such as mitoxantrone-loaded albumin microspheres, has shown reduced systemic toxicity in a murine breast cancer model. Additionally, intratumoral immunotherapy is highlighted for minimizing off-target toxicities compared to systemic delivery. These findings suggest that intratumoral approaches, like IP-001, may offer safety advantages by reducing systemic side effects.56789
Is the treatment IP-001 a promising treatment for solid cancers?
Yes, IP-001 is promising because it can be injected directly into tumors, which helps to boost the body's immune response against cancer while reducing side effects. This approach allows for high concentrations of the treatment in the tumor, making it more effective and safer than traditional methods.12356
Research Team
Diane Beatty, PhD
Principal Investigator
Immunophotonics, Inc.
Markus Jorger, MD
Principal Investigator
Cantonal Hospital of St. Gallen
Eligibility Criteria
This trial is for adults over 18 with Stage 3 or 4 colon cancer, non-small cell lung cancer, or soft tissue sarcoma who've tried up to four treatments without success. They need good blood, liver and kidney function, a life expectancy over six months, and tumors accessible for ablation no larger than 5 cm. Participants must not be pregnant and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- IP-001 (Virus Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immunophotonics, Inc.
Lead Sponsor